
    the study was prematurely terminated due to slow patient accrual and discontinuation of
    clinical development of moxr0916 due to sponsor's strategic priorities.
  
['urothelial carcinoma']
['moxr0916', 'atezolizumab']

        Inclusion Criteria:

          -  Age >= 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of <= 2

          -  Life expectancy >= 12 weeks

          -  Histologically or cytologically confirmed locally advanced or metastatic urothelial
             carcinoma (UC)

          -  Availability of a representative formalin-fixed paraffin-embedded tumor specimen

          -  No prior systemic therapy for inoperable locally advanced or metastatic UC

          -  Ineligible for cisplatin-based chemotherapy as defined by any one of the following
             criteria: Impaired renal function (glomerular filtration rate [GFR] > 30 but < 60
             milliliter/minute [mL/min]); National Cancer Institute Common Terminology Criteria for
             Adverse Events (NCI CTCAE) version (v) 4.0 Grade >= 2 audiometric hearing loss (of 25
             Decibel at two contiguous frequencies or more severe); NCI CTCAE v 4.0 Grade >= 2
             peripheral neuropathy; ECOG Performance Status of 2

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1

          -  Adequate hematologic and end-organ function

        Exclusion Criteria:

          -  Significant cardiovascular disease

          -  Known clinically significant liver disease

          -  Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3
             weeks prior to initiation of study treatment

          -  Prior treatment with CD137 or OX40 agonists, anti-cytotoxic T-lymphocyte-associated
             protein (CTLA4), anti-programmed death-1 (PD-1), anti- programmed death-ligand 1
             (PD-L1), anti-CD-27, anti- glucocorticoid-induced tumor necrosis factor receptor
             (GITR) therapeutic antibody or pathway-targeting agents

          -  Untreated central nervous system (CNS) metastases or active (progressing or requiring
             corticosteroids for symptomatic control) CNS metastases

          -  Any history of leptomeningeal disease

          -  Malignancies other than UC within 5 years prior to Cycle 1, Day 1

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or
             evidence of active pneumonitis on screening chest computed tomography scan

          -  Active hepatitis B and C virus infection

          -  Positive HIV test at screening

          -  Active tuberculosis

          -  Prior allogeneic stem cell or solid organ transplantation
      